Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: A report from the french national registry of primary immune deficiencies

Journal of Clinical Oncology

Volumn 33, Issue 2, 2015, Pages 202-208

  Suarez, Felipe ^a,b,c,d   Mahlaoui, Nizar ^a,b,c   Canioni, Danielle ^a,e   Andriamanga, Chantal ^b   D'Enghien, Catherine Dubois ^f   Brousse, Nicole ^a,e   Jais, Jean Philippe ^a,c   Fischer, Alain ^a,b,c,g   Hermine, Olivier ^a,b,c,d   Stoppa Lyonnet, Dominique ^e,f  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b French National Reference Center for Primary Immune Deficiency   (France)

^c Universite Sorbonne Paris Cite   (France)

^d CNRS   (France)

^e LIPADE   (France)

^f INSTITUT CURIE   (France)

^g l'alimentation et l'Environnement   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; ATAXIA TELANGIECTASIA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMA; COHORT ANALYSIS; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DIAGNOSIS; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RETROSPECTIVE STUDY; SUBSTITUTION THERAPY; T CELL LEUKEMIA; TREATMENT RESPONSE; ACUTE DISEASE; AGE; AGED; COMPLICATION; FRANCE; GENETICS; INCIDENCE; LEUKEMIA; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MORTALITY; MUTATION; NEOPLASMS; PROGNOSIS; REGISTER;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; ATAXIA TELANGIECTASIA; FEMALE; FRANCE; HODGKIN DISEASE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INCIDENCE; LEUKEMIA; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84920983463     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.5101     Document Type: Article

References (30)

1. Louis-Bar D: Sur un syndrome progressif comprenant des télangiectasies capillaires cutanées et conjonctivales symétriques, à disposition naevoïde et des troubles cérébelleux. Confin Neurol 4:32-42, 1941.
2. Boder E, Sedgwick RP: Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics 21:526-554, 1958.
3. McKinnon PJ: ATM and the molecular pathogenesis of ataxia telangiectasia. Annu Rev Pathol 7:303-321, 2012.
4. Savitsky K, Bar-Shira A, Gilad S, et al: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749-1753, 1995.
5. Shiloh Y, Ziv Y: The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14:197-210, 2013.
6. Kamsler A, Daily D, Hochman A, et al: Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer Res 61:1849-1854, 2001.
7. Valentin-Vega YA, Maclean KH, Tait-Mulder J, et al: Mitochondrial dysfunction in ataxiatelangiectasia. Blood 119:1490-1500, 2012.
8. Peterson RD, Kelly WD, Good RA: Ataxia-telangiectasia: It's association with a defective thymus, immunological-deficiency disease, and malignancy. Lancet 1:1189-1193, 1964.
9. Morrell D, Cromartie E, Swift M: Mortality and cancer incidence in 263 patients with ataxiatelangiectasia. J Natl Cancer Inst 77:89-92, 1986.
10. Levitt R, Pierre RV, White WL, et al: Atypical lymphoid leukemia in ataxia telangiectasia. Blood 52:1003-1011, 1978.
11. Stern MH, Theodorou I, Aurias A, et al: T-cell nonmalignant clonal proliferation in ataxia telangiectasia: A cytological, immunological, and molecular characterization. Blood 73:1285-1290, 1989.
12. Stern MH, Lipkowitz S, Aurias A, et al: Inversion of chromosome 7 in ataxia telangiectasia is generated by a rearrangement between T-cell receptor beta and T-cell receptor gamma genes. Blood 74:2076-2080, 1989.
13. Thick J, Sherrington PD, Fisch P, et al: Molecular analysis of a new translocation, t(X;14)(q28; q11), in premalignancy and in leukaemia associated with ataxia telangiectasia. Genes Chromosomes Cancer 5:321-325, 1992.
14. Stilgenbauer S, Schaffner C, Litterst A, et al: Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 3:1155-1159, 1997.
15. Stoppa-Lyonnet D, Soulier J, Laugé A, et al: Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood 91:3920-3926, 1998.
16. Monni O, Zhu Y, Franssila K, et al: Molecular characterization of deletion at 11q22.1-23.3 in mantle cell lymphoma. Br J Haematol 104:665-671, 1999.
17. Skowronska A, Parker A, Ahmed G, et al: Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol 30:4524-4532, 2012.
18. Taylor AM, Metcalfe JA, Thick J, et al: Leukemia and lymphoma in ataxia telangiectasia. Blood 87:423-438, 1996.
19. Sandoval C, Swift M: Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol 31:491-497, 1998.
20. Sandoval C, Swift M: Hodgkin disease in ataxia-telangiectasia patients with poor outcomes. Med Pediatr Oncol 40:162-166, 2003.
21. Swift M, Morrell D, Massey RB, et al: Incidence of cancer in 161 families affected by ataxiatelangiectasia. N Engl J Med 325:1831-1836, 1991.
22. Bienemann K, Burkhardt B, Modlich S, et al: Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (ataxia telangiectasia or Nijmegen-breakage syndrome): A retrospective survey. Br J Haematol 155:468-476, 2011.
23. Micol R, Ben Slama L, Suarez F, et al: Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol 128:382.e1-389.e1, 2011.
24. Reiman A, Srinivasan V, Barone G, et al: Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br J Cancer 105:586-591, 2011.
25. CEREDIH: The French PID Study Group: The French national registry of primary immunodeficiency diseases. Clin Immunol 135:264-272, 2010.
26. Gray R: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1141-1154, 1988.
27. Staples ER, McDermott EM, Reiman A, et al: Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene. Clin Exp Immunol 153:214-220, 2008.
28. Yamamoto ML, Maier I, Dang AT, et al: Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res 73:4222-4232, 2013.
29. Kulinski JM, Leonardo SM, Mounce BC, et al: Ataxia telangiectasia mutated kinase controls chronic gammaherpesvirus infection. J Virol 86: 12826-12837, 2012.
30. Sandlund JT, Hudson MM, Kennedy W, et al: Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. Pediatr Blood Cancer 61:360-362, 2014.